The experience of using triple targeted therapy (elexacaftor/ tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes

This article discusses the clinical experience of using triple targeted therapy (elexacaftor/tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes. The description includes details on the diagnostic process, the features of the disease course, and treatment approaches. In addition, the work pays special attention to the use of targeted drugs, as well as the need for an integrated approach to managing the condition of patients with combined disorders. To date, there has been insufficient research on the efficacy of the drug elexacaftor/ tezacaftor/ivacaftor and its effects on patients with comorbid conditions, particularly those suffering from cystic fibrosis-related diabetes.

The aim was to highlight modern research on this topic and to assess the effect of triple targeted therapy on the clinical manifestations of the disease.

Results. The patient showed significant improvement in the functional state of the lungs, control of blood glucose levels, and overall quality of life.

Conclusion. The article summarizes the importance of an individualized approach to therapy that considers both genetic and metabolic aspects of the disease. The conclusion emphasizes the importance of early, timely initiation of treatment to achieve optimal results and improve the prognosis of long-term life in patients with cystic fibrosis and related complications.

1. Reyderman M.I. [Cystic fibrosis: (genetics, pathogenesis, clinical features)]. Moscow: Meditsina, 1974 (in Russian).

2. Lopes-Pacheco M. CFTR modulators: shedding light on precision medicine for systic fibrosis. Front. Pharmacol. 2016; 7: 275. DOI: 10.3389/fphar.2016.00275.

3. Silva Filho L.V.R.F.D., Athanazio R.A., Tonon C.R. et al. Use of elexacaftor + tezacaftor + ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis. J. Bras. Pneumol. 2024; 49 (6): e20230187. DOI: 10.36416/1806-3756/e20230187.

4. Ministry of Health of the Russian Federation. [Clinical guidelines: Cystic fibrosis (mucoviscidosis)]. Moscow; 2020. Available at: https://apicr.minzdrav.gov.ru/api.ashx?op=GetClinrecPdf&id=372_1 (in Russian).

5. Amelina E.L., Kashirskaya N.YU., Kondratyeva E.I. et al. [Registry of cystic fibrosis patients in the Russian Federation. 2018]. Available at: https://mukoviscidoz.org/doc/registr/web_block_Registre_2018.pdf (in Russian).

6. Eckford P.D., Li C., Ramjeesingh M., Bear C.E. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 2012; 287 (44): 36639–36649. DOI: 10.1074/jbc.M112.393637.

7. Moheet A., Moran A. New concepts in the pathogenesis of cystic fibrosis-related diabetes. J. Clin. Endocrinol. Metab. 2022; 107 (6): 1503–1509. DOI: 10.1210/clinem/dgac020.

8. Putman M.S., Norris A.W., Hull R.L. et al. Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes. Diabetes. 2023; 72 (6): 677–689. DOI: 10.2337/db22-0949.

9. Moran A., Brunzell C., Cohen R.C. et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010; 33 (12): 2697–2708. DOI: 10.2337/dc10-1768.

10. Moran A., Pillay K., Becker D. et al. ISPAD clinical practice consensus guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr. Diabetes. 2018; 19 (Suppl. 27): 64–74. DOI: 10.1111/pedi.12732.

11. Moran A., Pyzdrowski K.L., Weinreb J. et al. Insulin sensitivity in cystic fibrosis. Diabetes. 1994; 43 (8): 1020–1026. DOI: 10.2337/diab.43.8.1020.

12. Union of Pediatricians of Russia, Association of Medical Geneticists, Association of Pediatricians of the Moscow Region. [Guidelines: Targeted therapy for cystic fibrosis (mucoviscidosis)]. 2023. Available at: https://ostrovaru.com/wp-content/uploads/2023/07/targetnaya_terapia_mv_metodrekom_2023.pdf (in Russian).

13. Norris A.V., Oud K. L., Merjane L. et al. Survival in an unfavorable environment: Langerhans islets in cystic fibrosis. J. Endocrinol. 2019; 241 (1): R35–R50. DOI: 10.1530/JOE-18-0468.

14. Bassi M., Strati M. F., Spiandorello G. et al. Effect of elecasaftor/tezacaftor/ivacaftor therapy on HbA1c levels and insulin requirement in patients with insulin-dependent diabetes associated with cystic fibrosis: a retrospective observational study. Life (Basel). 2024; 14 (10): 1309. DOI: 10.3390/life14101309.

15. Li A., Vigers T., Pyle L. et al. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor–ivacaftor. J. Cyst. Fibros. 2019; 18 (1): 144–149. DOI: 10.1016/j.jcf.2018.07.010.

16. Misgault B., Chatron E., Reynaud Q. et al. Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients. J. Cyst. Fibros. 2020; 19 (5): 712–716. DOI: 10.1016/j.jcf.2020.03.002.

17. Volkova N., Moy K., Evans J. et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from the US and UK national registries. J. Cyst. Fibros. 2020; 19 (1): 68–79. DOI: 10.1016/j.jcf.2019.05.015.

18. Hart N.J., Aramandla R., Poffenberger G. et al. Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight. 2018; 3 (8): e98240. DOI: 10.1172/jci.insight.98240.

19. Sun X., Yi Y., Xie W. et al. CFTR influences beta cell function and insulin secretion through non-cell autonomous exocrine-derived factors. Endocrinology. 2017; 158 (10): 3325–3338. DOI: 10.1210/en.2017-00187.

20. Taelman V., Declerck D., Van Biervlit S. et al. Effect of 18-month use of elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis. Clin. Nutr. ESPEN. 2023; 58: 73–78. DOI: 10.1016/j.clnesp.2023.08.028.